<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959110</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 694/63</org_study_id>
    <nct_id>NCT04959110</nct_id>
  </id_info>
  <brief_title>Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT</brief_title>
  <acronym>Citrate PK</acronym>
  <official_title>Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Citrate has been proposed as anticoagulation of choice in continuous renal replacement&#xD;
      therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of&#xD;
      citrate in liver failure patients who require CRRT with regional citrate anticoagulation&#xD;
      (RCA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aimed to evaluate citrate PKs, metabolic complications, and clinical outcomes&#xD;
      among critically ill acute liver failure (ALF) and acute on top chronic liver failure (ACLF)&#xD;
      patients receiving CRRT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Citrate clearance</measure>
    <time_frame>4 hours</time_frame>
    <description>Citrate clearance by body</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Citrate accumulation</measure>
    <time_frame>4 hours</time_frame>
    <description>Number of total calcium to ionized calcium ratio &gt; 2.5 with acidosis with hypocalcemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>2 hours</time_frame>
    <description>Time to maximum concentration of citrate at 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the time curve</measure>
    <time_frame>4 hours</time_frame>
    <description>Area under the plasma concentration-time curve of citrate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of systemic ionized calcium</measure>
    <time_frame>4 hours</time_frame>
    <description>Change in systemic ionized calcium in arterial blood gas during study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of ionized magnesium</measure>
    <time_frame>4 hours</time_frame>
    <description>Change in systemic ionized magnesium in arterial blood gas during study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of bicarbonate</measure>
    <time_frame>4 hours</time_frame>
    <description>Change of bicarbonate in arterial blood gas during study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of total calcium to systemic ionized calcium</measure>
    <time_frame>4 hours</time_frame>
    <description>Number of patients with total calcium to systemic ionized calcium &gt; 2.5 with or without metabolic acidosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Citrate Toxicity</condition>
  <condition>Regional Citrate Anticoagulation</condition>
  <condition>Liver Failure, Acute</condition>
  <condition>Liver Failure, Acute on Chronic</condition>
  <condition>Pharmacokinetic</condition>
  <condition>Continuous Renal Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>Acute Liver Failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute liver failure critically ill patients receiving CRRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute on top Chronic Liver Failure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute on top chronic liver failure critically ill patients receiving CRRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pharmacokinetic study</intervention_name>
    <description>Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L&#xD;
Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium&#xD;
In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter</description>
    <arm_group_label>Acute Liver Failure</arm_group_label>
    <arm_group_label>Acute on top Chronic Liver Failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Critically ill ALF or ACLF adult patients with AKI&#xD;
&#xD;
          -  aged â‰¥ 18 y old&#xD;
&#xD;
          -  Currently receiving CRRT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  severe acidosis (pH &lt; 7.1) or severe alkalosis (pH &gt; 7.55)&#xD;
&#xD;
          -  blood transfusion within 24 h prior to the study&#xD;
&#xD;
          -  use of citrate-containing medications&#xD;
&#xD;
          -  severe hypocalcemia (serum ionized calcium &lt; 0.8 mmol/L)&#xD;
&#xD;
          -  use of heparin as anticoagulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chulalongkorn university</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Nattachai Srisawat ,M.D.</investigator_full_name>
    <investigator_title>Director of Excellence Center for Critical Care Nephrology</investigator_title>
  </responsible_party>
  <keyword>Regional citrate anticoagulation</keyword>
  <keyword>Liver failure</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>CRRT</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

